PP
TBPH icon

Paloma Partners’s Theravance Biopharma TBPH Stock Holding History

Paloma Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,636
Closed -$203K – 2442
2020
Q2 		$203K Buy
+9,636
New +$248K ﹤0.01% 1683
2019
Q2 		– Sell
-10,088
Closed -$229K – 2155
2019
Q1 		$229K Buy
+10,088
New +$256K 0.01% 1446
2017
Q3 		– Sell
-13,995
Closed -$558K – 2417
2017
Q2 		$558K Sell
13,995
-6,563
-32% -$252K 0.01% 1482
2017
Q1 		$757K Buy
20,558
+7,080
+53% +$226K 0.01% 1403
2016
Q4 		$430K Buy
13,478
+477
+4% +$14.8K ﹤0.01% 1584
2016
Q3 		$471K Buy
13,001
+1,763
+16% +$49.1K 0.01% 1436
2016
Q2 		$255K Buy
+11,238
New +$243K ﹤0.01% 1845

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Paloma Partners's TBPH Position: Q3 2020 in Review

Paloma Partners sold out of Theravance Biopharma (TBPH) in Q3 2020, closing a stake of 9,636 shares — an estimated $203K sold.

Paloma Partners first reported a position in TBPH in Q2 2016 and held it in 7 quarters. The position peaked at $757K in Q1 2017. 118 funds tracked by Wall St. Rank hold TBPH as of Q3 2020.

  • Paloma Partners reported no remaining Theravance Biopharma position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 9,636 Theravance Biopharma shares in Q3 2020, an estimated $203K.
  • Paloma Partners first reported a position in Theravance Biopharma in Q2 2016 and held it in 7 quarters.
  • Paloma Partners's Theravance Biopharma position peaked at $757K in Q1 2017.
  • 118 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.